Skip to main content

NCT00574132 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carri

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers


CSR Summary

Not Available


Primary Citation

Not Available


Data Specification

Not yet available


Annotated CRF

Not yet available

Product Info

Generic Name
Bapineuzumab
Product Name
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
1,331
% Female
N/A
% White
N/A
Product Class
Monoclonal Antibody
Sponsor Protocol Number
ELN115727-301
Data Partner
Johnson & Johnson
Condition Studied
Alzheimer Disease
Mean/Median Age (Years)
N/A

Supporting Documentation

Clinical Study Report
Collected Datasets
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.